Last reviewed · How we verify
E2020-Donepezil hydrochloride
Donepezil hydrochloride is a cholinesterase inhibitor that works by increasing the concentration of acetylcholine in the brain, which helps to improve cognitive function in patients with Alzheimer's disease.
Donepezil hydrochloride is a cholinesterase inhibitor that works by increasing the concentration of acetylcholine in the brain, which helps to improve cognitive function in patients with Alzheimer's disease. Used for Moderate to severe dementia of the Alzheimer's type.
At a glance
| Generic name | E2020-Donepezil hydrochloride |
|---|---|
| Sponsor | Eisai Co., Ltd. |
| Drug class | Cholinesterase inhibitor |
| Target | Acetylcholinesterase |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the enzyme acetylcholinesterase, donepezil hydrochloride prevents the breakdown of acetylcholine, a neurotransmitter involved in memory and learning. This leads to an increase in acetylcholine levels in the brain, which can help to improve cognitive symptoms in patients with Alzheimer's disease. However, the exact mechanism of action is not fully understood and may involve other neurotransmitter systems as well.
Approved indications
- Moderate to severe dementia of the Alzheimer's type
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Fatigue
- Headache
Key clinical trials
- Investigating the Cholinergic Contribution to Gait Dysfunction in Parkinson's Disease (PHASE2)
- Donepezil Versus Non-drug Treatment in Alzheimer's Disease. (PHASE3)
- Ultrasound-Guided Stellate Ganglion Block for Alzheimer's Disease (NA)
- Clinical Evaluation on the Therapeutic Effect of Acupuncture Treatment for Alzheimer's Disease (NA)
- Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007) (PHASE1)
- Intravenous Infusion of Umbilical Cord Blood as an Adjunctive Treatment for Alzheimer's Disease (EARLY_PHASE1)
- Masitinib in Patients With Mild Alzheimer's Disease (PHASE3)
- Effect of Donepezil on Speech Recognition in Cochlear Implant Users (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- E2020-Donepezil hydrochloride CI brief — competitive landscape report
- E2020-Donepezil hydrochloride updates RSS · CI watch RSS
- Eisai Co., Ltd. portfolio CI